EVEROCAN everolimus 0.25 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

everocan everolimus 0.25 mg tablet blister pack

pharmacor pty ltd - everolimus, quantity: 0.25 mg - tablet, uncoated - excipient ingredients: ethanol absolute; lactose monohydrate; butylated hydroxytoluene; magnesium stearate; lactose; acetone; hypromellose; crospovidone - everolimus is indicated for the prophylaxis of organ rejection in adult patients at mild to moderate immunological risk receiving an allogeneic renal or cardiac transplant and in adult patients receiving an allogeneic hepatic transplant (see section 4.4 special warnings and precautions for use).

PHARMACOR EVEROLIMUS everolimus 0.25 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor everolimus everolimus 0.25 mg tablet blister pack

pharmacor pty ltd - everolimus, quantity: 0.25 mg - tablet, uncoated - excipient ingredients: butylated hydroxytoluene; lactose; ethanol absolute; hypromellose; magnesium stearate; lactose monohydrate; crospovidone; acetone - everolimus is indicated for the prophylaxis of organ rejection in adult patients at mild to moderate immunological risk receiving an allogeneic renal or cardiac transplant and in adult patients receiving an allogeneic hepatic transplant (see section 4.4 special warnings and precautions for use).

EVEROCAN everolimus 1 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

everocan everolimus 1 mg tablet blister pack

pharmacor pty ltd - everolimus, quantity: 1 mg - tablet, uncoated - excipient ingredients: lactose; acetone; butylated hydroxytoluene; magnesium stearate; ethanol absolute; lactose monohydrate; crospovidone; hypromellose - everolimus is indicated for the prophylaxis of organ rejection in adult patients at mild to moderate immunological risk receiving an allogeneic renal or cardiac transplant and in adult patients receiving an allogeneic hepatic transplant (see section 4.4 special warnings and precautions for use).

PHARMACOR EVEROLIMUS everolimus 0.5 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor everolimus everolimus 0.5 mg tablet blister pack

pharmacor pty ltd - everolimus, quantity: 0.5 mg - tablet, uncoated - excipient ingredients: butylated hydroxytoluene; crospovidone; ethanol absolute; hypromellose; lactose monohydrate; lactose; acetone; magnesium stearate - everolimus is indicated for the prophylaxis of organ rejection in adult patients at mild to moderate immunological risk receiving an allogeneic renal or cardiac transplant and in adult patients receiving an allogeneic hepatic transplant (see section 4.4 special warnings and precautions for use).

EVEROCAN everolimus 0.75 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

everocan everolimus 0.75 mg tablet blister pack

pharmacor pty ltd - everolimus, quantity: 0.75 mg - tablet, uncoated - excipient ingredients: hypromellose; butylated hydroxytoluene; ethanol absolute; acetone; crospovidone; lactose; magnesium stearate; lactose monohydrate - everolimus is indicated for the prophylaxis of organ rejection in adult patients at mild to moderate immunological risk receiving an allogeneic renal or cardiac transplant and in adult patients receiving an allogeneic hepatic transplant (see section 4.4 special warnings and precautions for use).

EVEROCAN everolimus 0.5 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

everocan everolimus 0.5 mg tablet blister pack

pharmacor pty ltd - everolimus, quantity: 0.5 mg - tablet, uncoated - excipient ingredients: lactose; ethanol absolute; magnesium stearate; lactose monohydrate; hypromellose; crospovidone; acetone; butylated hydroxytoluene - everolimus is indicated for the prophylaxis of organ rejection in adult patients at mild to moderate immunological risk receiving an allogeneic renal or cardiac transplant and in adult patients receiving an allogeneic hepatic transplant (see section 4.4 special warnings and precautions for use).

PHARMACOR EVEROLIMUS everolimus 0.75 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor everolimus everolimus 0.75 mg tablet blister pack

pharmacor pty ltd - everolimus, quantity: 0.75 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; lactose; crospovidone; butylated hydroxytoluene; magnesium stearate; acetone; ethanol absolute; hypromellose - everolimus is indicated for the prophylaxis of organ rejection in adult patients at mild to moderate immunological risk receiving an allogeneic renal or cardiac transplant and in adult patients receiving an allogeneic hepatic transplant (see section 4.4 special warnings and precautions for use).

CERTICAN 0.5 MG TABLETS Israel - English - Ministry of Health

certican 0.5 mg tablets

novartis israel ltd - everolimus - tablets - everolimus 0.5 mg - everolimus - everolimus - kidney and heart transplantationcertican ® is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving an allogeneic renal or cardiac transplant. in kidney and heart transplantation, certican should be used in combination with ciclosporin for microemulsion and corticosteroids.liver transplantationcertican is indicated for the prophylaxis of organ rejection in adult patients receiving a hepatic transplant. in liver transplantation, certican should be used in combination with tacrolimus and corticosteroids.

CERTICAN 0.75 MG TABLETS Israel - English - Ministry of Health

certican 0.75 mg tablets

novartis israel ltd - everolimus - tablets - everolimus 0.75 mg - everolimus - everolimus - kidney and heart transplantationcertican ® is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving an allogeneic renal or cardiac transplant. in kidney and heart transplantation, certican should be used in combination with ciclosporin for microemulsion and corticosteroids.liver transplantationcertican is indicated for the prophylaxis of organ rejection in adult patients receiving a hepatic transplant. in liver transplantation, certican should be used in combination with tacrolimus and corticosteroids.

CERTICAN 0.25 MG TABLETS Israel - English - Ministry of Health

certican 0.25 mg tablets

novartis israel ltd - everolimus - tablets - everolimus 0.25 mg - everolimus - everolimus - kidney and heart transplantationcertican ® is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving an allogeneic renal or cardiac transplant. in kidney and heart transplantation, certican should be used in combination with ciclosporin for microemulsion and corticosteroids.liver transplantationcertican is indicated for the prophylaxis of organ rejection in adult patients receiving a hepatic transplant. in liver transplantation, certican should be used in combination with tacrolimus and corticosteroids.